how to make milrinone
Milrinone is a phosphodiesterase-3 (PDE3) inhibitor used clinically as an inotropic and vasodilatory agent for heart failure. Its synthesis involves several organic chemistry steps starting from simple pyridine or pyridone precursors.
Searching sources...
Searching the Web
milrinone synthesis organic chemistry route
Reading File
Reading Web Page
https://en.wikipedia.org/wiki/Milrinone
Here is a thorough overview of milrinone - both its chemistry/synthesis and clinical context.
Milrinone
What It Is
Milrinone (IUPAC: 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile) is a bipyridine PDE-III inhibitor used IV for acute decompensated heart failure. It was originally synthesized at the Sterling Winthrop Research Institute in the 1980s as a chemical modification of amrinone.
- Molecular formula: C₁₂H₉N₃O
- Molar mass: 211.22 g/mol
- Melting point: 315 °C
- SMILES:
c1cnccc1-c2c(C)[nH]c(=O)c(C#N)c2
Chemical Synthesis
Milrinone has been synthesized by multiple routes, documented in peer-reviewed literature (Heterocycles journal) and Chinese pharmaceutical patents (CN 104326975, CN 104387320). The core challenge is building the 3,4'-bipyridyl scaffold with the 2-methyl, 5-cyano, and 6-oxo substituents on the dihydropyridinone ring.
Classic Route (Knoevenagel / Hantzsch-type condensation)
The most widely cited academic synthesis (Shiao et al., 1990; Singh, 1985) proceeds in two key stages:
Step 1 - Synthesis of the key intermediate: 2-methyl-3-(4-pyridyl)acrylonitrile (or analogous chalcone)
Cyanoacetamide is condensed with 4-pyridinecarboxaldehyde (isonicotinaldehyde) under basic conditions (e.g., piperidine or ammonium acetate catalyst) to give a Knoevenagel product - a 2-(4-pyridylmethylene)malononitrile or cyanoacrylate intermediate.
Step 2 - Cyclization to the dihydropyridinone
The intermediate is reacted with ethyl acetoacetate (or acetylacetone) in the presence of a base. The 1,6-dihydropyridinone ring forms via a Michael addition followed by cyclization and dehydration:
4-pyridinecarboxaldehyde + cyanoacetamide
→ (Knoevenagel condensation, piperidine catalyst, EtOH reflux)
→ α-cyano-4-pyridylmethylene acetamide intermediate
intermediate + ethyl acetoacetate (or acetylacetone)
→ (base-mediated cyclization, then acid workup)
→ 1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile
= MILRINONE
Alternative Route via 1-(4-Pyridyl)acetone
A later approach (Chinese patent CN 103848779, University of Jinan) uses 1-(4-pyridyl)acetone as a building block:
- 1-(4-pyridyl)acetone + cyanoacetamide + a carbonyl component → Hantzsch-type multicomponent condensation
- Cyclization and aromatization/oxidation give the pyridinone ring of milrinone
Industrial High-Purity Routes
Industrial patents (CN 104326975 and CN 104387320) focus on refining the synthesis to remove impurities and achieve pharmaceutical-grade purity. Key refinements include:
- Controlled temperature during cyclization (to minimize regioisomers)
- Recrystallization from DMF/water or acetonitrile
- Careful pH control during the Knoevenagel step
Key Reagents Summary
| Reagent | Role |
|---|---|
| 4-Pyridinecarboxaldehyde (isonicotinaldehyde) | Provides the pyridine ring |
| Cyanoacetamide | Provides the cyano and amide groups |
| Ethyl acetoacetate or acetylacetone | Provides the methyl group and the ketone for ring closure |
| Piperidine or ammonium acetate | Base/catalyst for Knoevenagel condensation |
| Ethanol or DMF | Solvent |
Regulatory and Safety Note
Milrinone is a prescription-only pharmaceutical in all jurisdictions (US: Rx-only, EU: Rx-only). Its synthesis and manufacture for human use requires regulatory authorization (FDA, EMA, etc.) and a licensed pharmaceutical manufacturing facility. The synthesis described here is from published academic literature for educational and research purposes.
Clinical Use (Brief)
Milrinone works by inhibiting PDE-III, which prevents breakdown of cAMP in cardiac and vascular smooth muscle. This leads to:
- Increased cardiac contractility (positive inotropy) and relaxation (lusitropy)
- Peripheral and pulmonary vasodilation
- Net increase in cardiac output with reduced filling pressures
It is administered IV (loading dose ~50 mcg/kg over 10 min, then 0.375-0.75 mcg/kg/min infusion), primarily in ICU/perioperative settings. Elimination half-life is ~2.3 hours; 85% excreted unchanged by the kidneys.
Key references: Singh B (1985) Heterocycles 23(6):1479; Shiao MJ et al. (1990) Heterocycles 31(3):523; Yan H et al. CN 104326975 (2015).
This is a shared conversation. Sign in to Orris to start your own chat.